(CercleFinance.com) – Lysogene rose by more than 4% on Thursday on the Paris Stock Exchange after taking stock of the schedule for the phase 2/3 clinical study on its gene therapy LYS-SAF302.
In a press release, the biopharmaceutical company now says it expects the next analysis of all the data from the patients included in the main cohort of the study, which concerns mucopolysaccharidosis type IIIA (MPS IIIA), a rare inherited metabolic disorder. which primarily affects the brain.
Lysogene plans to carry out, during the second quarter of 2022, work to compile and analyze all the data collected over the past three years, not only on cognitive development, but also on behavior, the acquisition of skills and patient quality of life.
Preliminary results from the main cohort of the clinical study, dubbed ‘AAVance’, are expected in the third quarter of 2022.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
